Determination of naftopidil enantiomers in rat plasma using chiral solid phases and pre-column derivatization high-performance liquid chromatography

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 907, Issue , 2012, Pages 140-145

  Liu, Xiawen ^a   Zhang, Yunying ^a   Yuan, Mu ^a   Sun, Yinxiang ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b The First People's Hospital in Zhuhai   (China)

Author keywords

Chiral column; Enantioselective pharmacokinetics; Naftopidil; Pre column derivatization

Indexed keywords

AGILENT; ANALYTES; BIOANALYTICAL; CHIRAL COLUMN; CHIRALPAK IA; DERIVATIZATION METHOD; DIASTEREOMERS; EMISSION WAVELENGTH; ENANTIOSELECTIVE; EXCITATION WAVELENGTH; FLUORESCENCE DETECTOR; HPLC METHOD; INTRAVENOUS ADMINISTRATION; LIQUID-LIQUID EXTRACTION; MOBILE PHASE; NAFTOPIDIL; PHARMACOKINETIC PARAMETERS; PHARMACOKINETIC STUDIES; PRECOLUMN DERIVATIZATIONS; QUANTIFICATION LIMIT; RAT PLASMA; SOLID PHASIS;

ACETONITRILE; BODY FLUIDS; ENANTIOMERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHANOL; PHARMACOKINETICS;

CHIRALITY;

NAFTOPIDIL;

ACCURACY; ALKALINITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHIRAL SOLIDE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; CONTROLLED STUDY; DERIVATIZATION; DIASTEREOISOMER; DRUG DETERMINATION; ENANTIOMER; ENVIRONMENTAL TEMPERATURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRECOLUMN DERIVATIZATION HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; RAT; REACTION TIME; ROOM TEMPERATURE; SOLID; STEREOCHEMISTRY; TEMPERATURE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; LINEAR MODELS; LIQUID-LIQUID EXTRACTION; MALE; NAPHTHALENES; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM;

RATTUS;

EID: 84867403701     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.09.021     Document Type: Article

References (19)

1. Roehrborn C.G. Rev. Urol. 2005, 7:S3.
2. Mirone V., Sessa A., Giuliano F., Berges R., Kirby M., Moncada I. Int. J. Clin. Pract. 2011, 65:1005.
3. Yamanaka N., Yamaguchi O., Kameoka H., Fukaya Y., Yokota T., Shiraiwa Y., Yokoyama J., Kumakawa K., Itou K., Kuma Y. Acta Urol. Jpn. (Hinyokika kiyo) 1991, 37:1759.
4. Ikegaki I. Folia Pharmacol. Jpn. (Nippon yakurigaku zasshi) 2000, 116:63.
5. Kanda H., Ishii K., Ogura Y., Imamura T., Kanai M., Arima K., Sugimura Y. Int. J. Cancer 2008, 122:444.
6. Nishino Y., Masue T., Miwa K., Takahashi Y., Ishihara S., Deguchi T. BJU Int. 2006, 97:747.
7. Takei R., Ikegakii I., Shibata K., Tsujimoto G., Asano T. Jpn. J. Pharmacol. 1999, 79:447.
8. Sugaya K., Nishijima S., Miyazato M., Ashitomi K., Hatano T., Ogawa Y. Neurosci. Lett. 2002, 328:74.
9. FDA'S Policy Statement for the Development of New Stereoisomeric Drugs, 1992. Available from: http://www.fda.gov/ohrms/dockets/dailys/01/Sep01/092001/01p_0428/VOL%200001/cp00001_tab_13.pdf.
10. Farthing M., Alstead E., Abrams S., Haug G., Johnston A., Hermann R., Niebch G., Ruus P., Molz K., Turner P. Postgrad. Med. J. 1994, 70:363.
11. Jinsong D., Xuehua J., Hao Z. J. Chin. Pharm. Sci. 2000, 9:200.
12. Zhao X., Sun P., Zhou Y., Liu Y., Zhao D., Cui Y., Sun Z. Chin. J. Clin. Pharmacol. 2007, 23:209.
13. Aboul-Enein H.Y., Serignese V. Cellulose 1995, 2:215.
14. Sun Y.X., Huang B.Y., Yuan M., Shi J.S. J. Chin. Pharm. Sci. 2009, 18:61.
15. Himmel H.M. Cardiovasc. Drug Rev. 1994, 12:32.
16. Zhang T., Franco P. Chiral Technol. Eur. 2004, 1.
17. Li Li., Xin Z., Mu Y., Hong Z., Daoping W. Acta Pharm. Sin. 2006, 41:1.
18. Niebch G., Borbe H.O., Besenfelder E. J. Chromatogr. B: Biomed. Appl. 1990, 534:247.
19. Peter G., Niebch G., Locher M., Borbe H. Arzneimittelforschung 1991, 41:924.